Title:
BISPECIFIC ANTI-HER2 ANTIBODY
Document Type and Number:
WIPO Patent Application WO/2018/014864
Kind Code:
A1
Abstract:
Humanized bispecific anti-HER2 antibodies that comprise one antigen binding site containing variable regions of heavy and light chain of trastuzumab, and another antigen binding site containing variable regions of heavy and light chain of pertuzumab. The bispecific anti-HER2 antibody is effective for treating cancer, such as breast cancer, gastric cancer, or ovarian cancer. Preferred bispecific anti-HER2 antibodies are afucosylated antibodies. Also provided Chinese Hamster ovary(CHO) mutant cell line that has a dysfunctional Slc35C1 gene, which is the only dysfunctional gene in the mutant that affects glycan regulation.
More Like This:
Inventors:
LI FENG (CN)
ZHANG BOYAN (CN)
YE PEI (CN)
ZHAO JIAN (CN)
HUANG SIJIA (CN)
JIN CHUNYANG (CN)
ZHANG BOYAN (CN)
YE PEI (CN)
ZHAO JIAN (CN)
HUANG SIJIA (CN)
JIN CHUNYANG (CN)
Application Number:
PCT/CN2017/093816
Publication Date:
January 25, 2018
Filing Date:
July 21, 2017
Export Citation:
Assignee:
BEIJING MABWORKS BIOTECH CO LTD (CN)
International Classes:
C07K16/46; A61K39/395; A61P35/00; C07K16/30; C12N5/16; C12N15/13
Domestic Patent References:
| WO2015077891A1 | 2015-06-04 | |||
| WO2015091738A1 | 2015-06-25 | |||
| WO2015164665A1 | 2015-10-29 |
Foreign References:
| CN200510064335A | 2005-04-14 |
Other References:
MENG, Y. C .: "Effective suppression of breast tumor growth by a bispecific antibody targeting distinct ErbB2 epitopes", CHINESE MASTER'S THESES FULL-TEXT DATABASE (MEDICINE AND HEALTH SCIENCES, 15 May 2014 (2014-05-15), XP055588776
CHAN, K. F. ET AL.: "Inactivation of GDP-fucose transporter gene (Slc35cl) in CHO cells by ZFNs, TALENs and CRISPR-Cas9 for production of fucose-free antibodies", BIOTECHNOLOGY JOURNAL, vol. 11, 16 October 2015 (2015-10-16), pages 399 - 414, XP055455163
TANG, Q. ET AL.: "Development of antibody drugs targeting against HER2 for cancer therapy", ACTA PHARMACEUTICA SINICA., vol. 47, no. 10, 12 October 2012 (2012-10-12), pages 1297 - 1305, XP009514505, ISSN: 0513-4870
GUTIERREZ, CR. SCHIFF: "HER2: biology, detection, and clinical implications", ARCH PATHOL LAB MED, vol. 135, no. 1, 2011, pages 55 - 62
GUTIERREZ ET AL., ARCH PATHOL LAB MED, vol. 135, no. 1, 2011, pages 55 - 62
ECCLES, INT J DEV BIOL, vol. 55, no. 7-9, 2011, pages 685 - 96
NAT MED, vol. 6, 2000, pages 443 - 6
KOHRT ET AL., J CLIN INVEST, vol. 122, no. 3, 2012, pages 1066 - 75
FRANKLIN, M.C. ET AL.: "Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex", CANCER CELL, vol. 5, no. 4, 2004, pages 317 - 28, XP002372929, DOI: 10.1016/S1535-6108(04)00083-2
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY
"GenBank", Database accession no. BAE16173.1
See also references of EP 3487888A4
CHAN, K. F. ET AL.: "Inactivation of GDP-fucose transporter gene (Slc35cl) in CHO cells by ZFNs, TALENs and CRISPR-Cas9 for production of fucose-free antibodies", BIOTECHNOLOGY JOURNAL, vol. 11, 16 October 2015 (2015-10-16), pages 399 - 414, XP055455163
TANG, Q. ET AL.: "Development of antibody drugs targeting against HER2 for cancer therapy", ACTA PHARMACEUTICA SINICA., vol. 47, no. 10, 12 October 2012 (2012-10-12), pages 1297 - 1305, XP009514505, ISSN: 0513-4870
GUTIERREZ, CR. SCHIFF: "HER2: biology, detection, and clinical implications", ARCH PATHOL LAB MED, vol. 135, no. 1, 2011, pages 55 - 62
GUTIERREZ ET AL., ARCH PATHOL LAB MED, vol. 135, no. 1, 2011, pages 55 - 62
ECCLES, INT J DEV BIOL, vol. 55, no. 7-9, 2011, pages 685 - 96
NAT MED, vol. 6, 2000, pages 443 - 6
KOHRT ET AL., J CLIN INVEST, vol. 122, no. 3, 2012, pages 1066 - 75
FRANKLIN, M.C. ET AL.: "Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex", CANCER CELL, vol. 5, no. 4, 2004, pages 317 - 28, XP002372929, DOI: 10.1016/S1535-6108(04)00083-2
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY
"GenBank", Database accession no. BAE16173.1
See also references of EP 3487888A4
Attorney, Agent or Firm:
SBZL IP LAW OFFICE (CN)
Download PDF:
Previous Patent: CRYSTAL AND SALT OF NITROIMIDAZOLE, AND MANUFACTURING METHOD THEREOF
Next Patent: AIEGENS FOR CANCER CELL IMAGING
Next Patent: AIEGENS FOR CANCER CELL IMAGING